MARKET

AVBP

AVBP

Arrivent Biopharma Inc
NASDAQ
13.51
+0.02
+0.11%
After Hours: 13.50 -0.01 -0.04% 19:30 11/11 EST
OPEN
13.62
PREV CLOSE
13.49
HIGH
13.91
LOW
13.38
VOLUME
911.25K
TURNOVER
--
52 WEEK HIGH
35.83
52 WEEK LOW
11.36
MARKET CAP
698.52M
P/E (TTM)
-3.6784
1D
5D
1M
3M
1Y
5Y
1D
ArriVent Biopharma price target raised to $23 from $20 at Citi
TipRanks · 1d ago
ArriVent Biopharma price target raised to $24 from $21 at Truist
TipRanks · 1d ago
ArriVent BioPharma Price Target Raised to $24.00/Share From $21.00 by Truist Securities
Dow Jones · 1d ago
ArriVent BioPharma Is Maintained at Buy by Truist Securities
Dow Jones · 1d ago
Truist Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $24
Benzinga · 1d ago
ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Oppenheimer
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Cormedix (CRMD) and Hims & Hers Health (HIMS)
TipRanks · 1d ago
Buy Rating Reiterated as ALPACCA Progress and Pipeline Catalysts Support Unchanged $29 Price Target
TipRanks · 1d ago
More
About AVBP
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4.

Webull offers Arrivent Biopharma Inc stock information, including NASDAQ: AVBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVBP stock methods without spending real money on the virtual paper trading platform.